Stem cell therapy for premature ovarian insufficiency: a review of clinical evidence and therapeutic strategies.
10.3724/zdxbyxb-2025-0148
- Author:
Zixin CHENG
1
,
2
;
Dongmei LAI
3
Author Information
1. Department of Gynecology, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China. cchengzixin@
2. com.
3. Department of Gynecology, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China. laidongmei@hotmail.com.
- Publication Type:Journal Article
- Keywords:
Clinical trial;
Individualized treatment;
Premature ovarian failure;
Premature ovarian insufficiency;
Review;
Stem cell transplantation
- From:
Journal of Zhejiang University. Medical sciences
2025;():1-10
- CountryChina
- Language:Chinese
-
Abstract:
Premature ovarian insufficiency (POI), characterized by the decline of ovarian function before age 40, significantly compromises fertility and long-term health of patients. Stem cell therapy has emerged as a promising approach for POI. This review synthesizes clinical evidence from studies utilizing cells sourced from adult tissues (e.g., adipose derived mesenchymal stem cells, bone marrow mesenchymal stem cells, peripheral blood stem cells) and perinatal tissues (e.g., human amniotic epithelial cells, umbilical cord-derived mesenchymal stem cells). Evidence suggests that stem cell transplantation can improve ovarian reserve, reflected by reduced follicle-stimulating hormone levels and increased estradiol and anti-Müllerian hormone levels, with some patients resuming menstruation and achieving pregnancy. However, treatment efficacy is influenced by patient-specific factors and clinical protocols. Optimizing stem cell transplantation protocols is pivotal for enhancing their clinical efficacy and safety. This article elaborates on key optimization strategies, including transplantation timing, delivery routes, and combination therapies, proposing that early intervention and personalized regimens may improve outcomes. We also discuss patient benefits (such as pregnancy outcomes and quality of life) and treatment safety. Future research should focus on refining personalized strategies, investigating the therapeutic potential of stem cell-derived agents, and establishing long-term follow-up, thereby advancing POI therapy toward precision medicine and standardized application.
